Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nirmatrelvir Plus Ritonavir: First Approval
Yvette N. Lamb
Drugs (2022) Vol. 82, Iss. 5, pp. 585-591
Open Access | Times Cited: 240

Showing 26-50 of 240 citing articles:

Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Gupta, Oleksandr V. Savytskyi, Matt Coban, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101151-101151
Open Access | Times Cited: 30
SS148 and WZ16 inhibit the activities of nsp10-nsp16 complexes from all seven human pathogenic coronaviruses
Fengling Li, Pegah Ghiabi, Taraneh Hajian, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2023) Vol. 1867, Iss. 4, pp. 130319-130319
Open Access | Times Cited: 21
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 18
Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
Yangqing Zhan, Zhengshi Lin, Jingyi Liang, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102359-102359
Open Access | Times Cited: 17
pH-Sensitive and Biodegradable Mn3(PO4)2·3H2O Nanoparticles as an Adjuvant of Protein-Based Bivalent COVID-19 Vaccine to Induce Potent and Broad-Spectrum Immunity
Shihao Zhou, Ru-Yan Zhang, Zi-Wei You, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 7, pp. 8914-8926
Closed Access | Times Cited: 16
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 112-112
Open Access | Times Cited: 6
Carrimycin inhibits coronavirus replication by decreasing the efficiency of programmed –1 ribosomal frameshifting through directly binding to the RNA pseudoknot of viral frameshift-stimulatory element
Hongying Li, Jianrui Li, Jiayu Li, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2567-2580
Open Access | Times Cited: 6
Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2
Kateryna Lohachova, Anastasiia S . Sviatenko, Alexander Kyrychenko, et al.
Journal of Applied Pharmaceutical Science (2024)
Open Access | Times Cited: 6
Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir
Laura Krismer, Helge Schöppe, Stefanie Rauch, et al.
npj Viruses (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 6
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Yi‐Ru Bai, Dong‐Jie Seng, Ying Xu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116706-116706
Closed Access | Times Cited: 6
Bisubstrate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase
Eunkyung Jung, Rubén Soto-Acosta, Jiashu Xie, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 9, pp. 1477-1484
Open Access | Times Cited: 27
Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)
Hongyan Li, Menghan Gao, Hailong You, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e148-e154
Open Access | Times Cited: 27
Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020
Roufen Chen, Yali Gao, Han Liu, et al.
RSC Medicinal Chemistry (2022) Vol. 14, Iss. 1, pp. 9-21
Open Access | Times Cited: 25
Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS‐CoV‐2 Omicron variants
Yu Wang, Danyang Zhao, Xinbing Liu, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 25
COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19
Tzuriel Sapir, Zaelig Averch, Brian Lerman, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8606-8606
Open Access | Times Cited: 24
Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond
Aileen Faist, Josua Janowski, Sriram Kumar, et al.
Cells (2022) Vol. 11, Iss. 14, pp. 2198-2198
Open Access | Times Cited: 23
Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site
Vera Jannie Elisabeth van Vliet, Nhan Huynh, Judith Palà, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 12, pp. e1011065-e1011065
Open Access | Times Cited: 23
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
Claudia Alteri, Valeria Fox, Rossana Scutari, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 22
Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma
Mohamed S. Imam, Ahmed H. Abdelazim, Afnan S. Batubara, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease
Joseph Clayton, Vinícius M. de Oliveira, Mohamed Fouad Ibrahim, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 11, pp. 3521-3533
Open Access | Times Cited: 15
Key allosteric and active site residues of SARS-CoV-2 3CLpro are promising drug targets
Kenana Al Adem, Juliana C. Ferreira, Samar Fadl, et al.
Biochemical Journal (2023) Vol. 480, Iss. 11, pp. 791-813
Open Access | Times Cited: 15
Synthetic Approaches to the New Drugs Approved During 2021
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10150-10201
Closed Access | Times Cited: 15
A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects
Xin‐Mei Yang, Yang Yang, Bu‐Fan Yao, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 191, pp. 106598-106598
Open Access | Times Cited: 14
SARS-CoV-2 omicron variants are susceptible in vitro to Artemisia annua hot water extracts
Manoj S. Nair, Yiming Huang, M. Wang, et al.
Journal of Ethnopharmacology (2023) Vol. 308, pp. 116291-116291
Open Access | Times Cited: 13
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Matteo Pavan, Stefano Moro
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4401-4401
Open Access | Times Cited: 13

Scroll to top